1. , , , et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–92.
2. . Hormone Therapy and the Brain: a Clinical Perspective on the Role of Estrogen. New York: Parthenon Publishing, 2000.
3. . The endocrinology of the menopause. Maturitas. 1996;23:129–36.
4. . Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol. 2005;67:335–76.
5. , , , et al. Neuroprotection against oxidative stress by estrogens: structure–activity relationship. Mol Pharmacol. 1997;51:535–41.
6. , , . Estrogen binding and estrogen receptor characterization (ERα and ERβ) in the cholinergic neurons of the rat basal forebrain. Neuroscience. 2000;96:41–9.
7. . Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol. 1985;89:484–90.
8. , . Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging. 2000;21:373–83.
9. , , , et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA. 1999;281:1197–202.
10. , , , et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause. 2006;13:411–22.
11. , , , . Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain. Neurology. 2000;54:2212–17.
12. , , , et al. Modulation of Aβ peptides by estrogen in mouse models. J Neurochem. 2002;80:191–6.
13. , , , et al. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann N Y Acad Sci. 2005;1052:210–24.
14. , , , et al. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci. 2007;27:13357–65.
15. , , , et al. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol. 1997;143:313–18.
16. , , , et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA. 1997;278:1349–56.
17. . Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol Aging. 2000;21:107–16.
18. , , , et al. Hormone replacement therapy and incidence of Alzheimer's disease on older women: the Cache County study. JAMA. 2002;288:2123–9.
19. , . Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med. 1996;156:2213–17.
20. , , , et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429–32.
21. , . Hormone therapy and risk of Alzheimer disease: a critical time. JAMA. 2002;288:2170–2.
22. . Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci. 2005;1052:57–74.
23. , . Neurotrophin expression in the reproductively senescent forebrain is refractory to estrogen stimulation. Neurobiol Aging. 2001;22:309–19.
24. , , , et al. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci. 2000;20:8604–9.
25. , , , , . Onset of estrogen replacement has a critical effect on synaptic density of CA1 hippocampus in ovariectomized adult rats. Menopause. 2003;10:406–11.
26. , , , et al. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci USA. 2007;104:6013–18.
27. , . The cognitive effects of ovariectomy and estrogen replacement are modulated by aging. Neuroscience. 2003;119:821–30.
28. , , . Estradiol replacement enhances working memory in middle-aged rats when initiated immediately after ovariectomy but not after a long-term period of ovarian hormone deprivation. Endocrinology. 2006;147:607–14.
29. . Cardiovascular disease and Alzheimer's disease: common links. J Intern Med. 2006;260:211–23.
30. , , , . Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197–204.
31. , , , et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol. 2001;21:1955–61.
32. , , , et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939–53.
33. , , , et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535–45.
34. . Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007;14:373–84.
35. , , , et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007;13:1185–92.
36. , , , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–77.
37. , . “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab. 1996;81:2545–9.
38. , , , , . Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav. 1998;34:171–82.
39. , , , , . The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101:485–512.
40. , , , . Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489–99.
41. , . Hormone Replacement Therapy: Knowledge and Use in the United States. Hyattsville, MD: National Center for Health Statistics, 2001.
42. , , , et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295–301.
43. , , , et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA. 2000;283:1007–15.
44. , , , et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology. 2001;57:605–12.
45. , , , et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. JAMA. 2004;291:2947–58.
46. , , , et al. The effect of estrogen with progestin treatment on global cognitive function in postmenopausal women: results from the Women's Health Initiative Memory Study. JAMA. 2003;289:2663–72.
47. , , , et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study. JAMA. 2004;291:2959–68.
48. , , , et al. Prior use of hormone therapy and incident Alzheimer's disease in the Women's Health Initiative Memory Study. Neurology. 2007;68(suppl. 1):A205.
49. . Hormone therapy and Alzheimer's disease: benefit or harm? Expert Opin Pharmacother. 2004;5:389–406.
50. . Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience. 2006;138:1031–9.
51. , , , , . Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143:971–8.
52. , , , , . Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry. 2005;76:103–5.
53. , , , et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994;140:262–7.
54. , , , et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease. Arch Neurol. 2001;58:435–40.
55. , , . Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology. 2004;63:101–7.
56. , , , et al. Hormone replacement therapy and reduced cognitive decline in older women: the Cache County study. Neurology. 2001;57:2210–16.
57. , . Surgical versus natural menopause: cognitive issues. Menopause. 2007;14:572–9.
58. , , , et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006;91:1802–10.
59. , , , et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/Progestin Replacement Study. Am J Med. 2002;113:543–8.
60. , , , et al. Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol. 2005;192:387–93.
61. , , , et al. 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging. 2006;27:141–9.
62. , , , et al. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. Arch Neurol. 2006;63:945–50.
63. , , , et al. Natural history of menopause symptoms in primary care patients: a MetroNet study. J Am Board Fam Pract. 2005;18:374–82.
64. , , , , . Estrogen exposures and memory at midlife: a population-based study of women. Neurology. 2003;60:1369–71.
65. , , . Endogenous estrogen is not associated with cognitive performance before, during, or after menopause. Menopause. 2007;14:425–31.
66. , , , et al. Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the study of women's health across the nation (SWAN). J Women's Health. 2007;16:331–44.
67. , , , , . A longitudinal study of cognition change during early menopausal transition in a rural community. Maturitas. 2006;53:447–53.
68. , , , et al. Cognitive function across the life course and the menopausal transition in a British birth cohort. Menopause. 2006;13:19–27.
69. , , , , . Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology. 2007;69:1322–30.
70. , , . Memory functioning among midlife women: observations from the Seattle Midlife Women's Health Study. Menopause. 2000;7:257–65.
71. , , , et al. Better oral reading and short-term memory in midlife, postmenopausal women taking estrogen. Menopause. 2003;10:420–6.
72. , . Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485–95.
73. , , , et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69:1074–83.
74. , , , et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause. 2006;13:28–36.
75. , , , , . Early postmenopausal hormone replacement therapy may prevent cognitive impairment later in life. Menopause. 2005;12:12–17.
76. . Estrogen as treatment for Alzheimer disease [letter]. JAMA. 2000;284:307–8.
77. , , , , . Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab. 2008;93:131–8.
78. , . Hysterectomy, oophorectomy, and cognitive function in older women. J Am Geriatr Soc. 2002;50:55–61.